Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440707 · ClinicalTrials.gov registry record · Phase 2
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
A Phase 2 study of Acute Ischemic Stroke, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT06440707 is a Phase 2 study of Acute Ischemic Stroke that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 120 participants, below the 347-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06440707, a Phase 2 study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the brain and rescue the brain tissue at risk of injury. The primary aim is to find an optimal dose of this therapy that is both adequately safe and effective on imaging markers of brain tissue rescue.
Conditions Studied
Interventions
- DEVICE High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)
- DEVICE Sham tDCS
Study Locations (3)
California
- University of California- Los Angeles (UCLA) - Los Angeles
Maryland
- Johns Hopkins Medical Center - Baltimore
North Carolina
- Duke Medical Center Hospital - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06440707
The ClinicalTrials.gov registry entry for NCT06440707 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (65% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS) is the first listed.
NCT06440707 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06440707 about?
NCT06440707 is a clinical study titled "Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke". Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the de...
What is the current status of trial NCT06440707?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-07-15. Estimated completion is 2030-08-01.
What conditions does trial NCT06440707 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT06440707?
The interventions under investigation include: High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS) (DEVICE), Sham tDCS (DEVICE).
Who is sponsoring clinical trial NCT06440707?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06440707 being conducted?
This trial has 3 study locations across California, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
COMPLETED · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.